The successes and challenges of open-source biopharmaceutical innovation

Expert Opinion on Drug Discovery

Volumn 9, Issue 5, 2014, Pages 459-465

  Allarakhia, Minna ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Big biopharmaceutical data; Biopharmaceutical value creation; Common value of knowledge; Open source biopharmaceutical innovation

Indexed keywords

ACCESS TO INFORMATION; CROWDSOURCING; DATA BASE; INTEGRATION; OUTCOME ASSESSMENT; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; STANDARDIZATION; DRUG DEVELOPMENT; DRUG INDUSTRY; MASS COMMUNICATION; METHODOLOGY; ORGANIZATION; PHARMACEUTICS; PROCEDURES; PROGRAM DEVELOPMENT;

BIOPHARMACEUTICS; DIFFUSION OF INNOVATION; DRUG DISCOVERY; DRUG INDUSTRY; ORGANIZATIONAL INNOVATION; PROGRAM DEVELOPMENT; RESEARCH DESIGN;

EID: 84899065045     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.905539     Document Type: Review

References (19)

1. Allarakhia M, Kilgour DM, Fuller D. Modeling the incentive to participate in open source biopharmaceutical innovation. R&D Management 2010;40:50-66
2. Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther 2013;7:753-66
3. Gao Z, Li H, Zhang H, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008;9:104
4. Gu?nther S, Kuhn M, Dunkel M, et al. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 2008;36(Database issue):D919-22 (Pubitemid 351149845)
5. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011;39(Database issue):D1035-41
6. Taboureau O, Nielsen SK, Audouze K, et al. ChemProt; a disease chemical biology database. Nucleic Acids Res 2011;39(Database issue):D367-72
7. Available from: openbabel.org [Accessed January 29 2014]
8. Available from: www.thesgc.org [Accessed January 2014]
9. Bayer HealthCare to Join Not-For-Profit SGC to Accelerate Research in Epigenetics. Bayer. 2013. Available from: http://www.newswire.ca/en/story/ 1281679/bayer-healthcare-to-join-not-forprofit- structural-genomics-consortium- toaccelerate- research-in-epigenetics [Last accessed January 2014]
10. Available from: www.pistoiaalliance.org [Accessed January 2014]
11. Available from: www.openphacts.org [Accessed January 2014]
12. Hunter J, Stephens S. Is open innovation the way forward for big pharma? Nat Rev Drug Discov 2010;9:87-8
13. Available from: openinnovation.lilly.com [Accessed January 2014]
14. Available from: http://sagebase.org/tag/ arch2pocm/ [Accessed January 2014]
15. Masum H. Insider Views of Collaborative R&D for Health: Q&A with Aled Edwards. Center for Global Health Policy R&D Assessment. 2012. Available from: http:// healthresearchpolicy.org/blog/2012/nov/ 1/insider-views-collaborative-rd-health-qaaled- edwards [Accessed January 2014]
16. Niesen P, Rockhold F. Access to patientlevel data from Glaxosmithkline clinical trials. N Engl J Med 2013;369:475-8
17. Available from: sagebase.org/synapse [Accessed January 2014]
18. Reichman JH, Uhlir PF. A contractually reconstructed research commons for scientific data: international considerations. In: Essanu JM, Uhlir PF, editors, Open access and the public domain in digital data and information for science: proceedings of an international symposium. National Academics Press, Washington; 2004. p. 98-102
19. Available from: www.osdd.net [Accessed January 2014]